Immuron LtdNASDAQ:IMRN
- LAST PRICE1.8799
- TODAY'S CHANGE (%)-0.0292 (-1.5295%)
- Bid / Lots1.7500/ 3
- Ask / Lots2.2500/ 5
- Open / Previous Close1.8600 / 1.9091
- Day Range
- 52 Week Range
- Volume4,562
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMRN |
|---|---|---|
| 09:32 ET | 1340 | 1.8001 |
| 10:08 ET | 600 | 1.91 |
| 10:47 ET | 400 | 1.8059 |
| 02:09 ET | 350 | 1.83 |
| 02:20 ET | 470 | 1.805 |
| 02:56 ET | 200 | 1.83 |
| 03:03 ET | 100 | 1.815 |
| 03:06 ET | 377 | 1.83 |
| 03:10 ET | 200 | 1.83 |
| 03:17 ET | 100 | 1.84 |
| 03:48 ET | 180 | 1.8799 |
Yesterday
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event, from 6:33PM ET on Thursday Nov 21, 2024 by Dow Jones
6:33PM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 18, 2024
Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event, from 8:31AM ET on Monday Nov 18, 2024 by Dow Jones
8:31AM ET on Monday Nov 18, 2024 by Dow Jones
Oct 29, 2024
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now, from 7:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
7:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
Industry Peers
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Immuron Ltd | --- | 0.0x | --- |
Company Information
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.
Contact Information
- Headquarters
- L 3 62 Lygon StMELBOURNE, VIC, Australia 3053
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Paul Brennan
- Chief Executive Officer
- Steven Lydeamore
- Chief Financial Officer, Company Secretary
- Phillip Hains
- Chief Operating Officer
- Jerry Kanellos
- Non-Executive Director
- Jeannette Joughin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | --- |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | --- |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | --- |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
